This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 2CX
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Competidores de ChemoCentryx, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$51.89 |
| 52 Week High | US$52.79 |
| 52 Week Low | US$15.40 |
| Beta | 1.23 |
| 1 Month Change | 1.27% |
| 3 Month Change | 143.79% |
| 1 Year Change | 78.99% |
| 3 Year Change | 668.74% |
| 5 Year Change | 815.01% |
| Change since IPO | 536.69% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 2CX | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -0.9% | -4.9% | -1.5% |
| 1Y | 79.0% | -19.9% | 0.9% |
Rentabilidad vs. Industria: 2CX exceeded the German Biotechs industry which returned -16.5% over the past year.
Rentabilidad vs. Mercado: 2CX exceeded the German Market which returned -27.1% over the past year.
Volatilidad de los precios
| 2CX volatility | |
|---|---|
| 2CX Average Weekly Movement | 29.9% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 2CX's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 2CX's weekly volatility has increased from 17% to 30% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1996 | 178 | n/a | www.chemocentryx.com |
Resumen de fundamentos de ChemoCentryx, Inc.
| Estadísticas fundamentales de 2CX | |
|---|---|
| Capitalización bursátil | €3.81b |
| Beneficios(TTM) | -€135.70m |
| Ingresos (TTM) | €38.01m |
100.3x
Ratio precio-ventas (PS)-28.1x
Ratio precio-beneficio (PE)¿Está 2CX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 2CX | |
|---|---|
| Ingresos | US$37.28m |
| Coste de los ingresos | US$71.86m |
| Beneficio bruto | -US$34.58m |
| Otros gastos | US$98.51m |
| Beneficios | -US$133.09m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.85 |
| Margen bruto | -92.76% |
| Margen de beneficio neto | -357.01% |
| Ratio deuda/patrimonio | 10.5% |
¿Cómo se ha desempeñado 2CX a largo plazo?
Ver rendimiento hist órico y comparativa